NASDAQ: ALLR
Allarity Therapeutics Inc Stock

$1.14+0.07 (+6.54%)
Updated Apr 29, 2025
ALLR Price
$1.14
Fair Value Price
$0.01
Market Cap
$19.40M
52 Week Low
$0.61
52 Week High
$103.80
P/E
-0.07x
P/B
1.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.92
Operating Cash Flow
-$17M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ALLR Overview

Allarity Therapeutics is a biopharma company developing oncology products and drugs for the personalized treatment of cancer. The company uses Drug Response Predictor (DRP®) technology to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures. Its pipeline products include Dovitinib, Stenoparib, Ixempra, and other formulations. Allarity was incorporated in 2004 and is headquartered in Cambridge, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ALLR's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ALLR
Ranked
#386 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ALLR news, forecast changes, insider trades & much more!

ALLR News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALLR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALLR ($1.14) is overvalued by 11,518.56% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALLR ($1.14) is not significantly undervalued (11,518.56%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALLR due diligence checks available for Premium users.

Valuation

ALLR fair value

Fair Value of ALLR stock based on Discounted Cash Flow (DCF)

Price
$1.14
Fair Value
$0.01
Overvalued by
11,518.56%
ALLR ($1.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALLR ($1.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALLR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.07x
Industry
-158.75x
Market
29.19x

ALLR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.64x
Industry
4.37x
ALLR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALLR's financial health

Profit margin

Revenue
$0.0
Net Income
-$7.5M
Profit Margin
0%
ALLR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$22.7M
Liabilities
$10.8M
Debt to equity
0.92
ALLR's short-term assets ($22.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALLR's short-term assets ($22.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALLR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALLR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$0.0
Financing
$4.2M
ALLR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALLR vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ALLRD$19.40M+6.54%-0.07x1.64x
PASG$19.39M-4.29%-0.29x0.32x
PMN$19.06M-3.32%5.30x1.16x
QTTBC$18.97M-7.72%-0.30x3.34x
ELEV$20.49M-2.81%-0.44x0.34x

Allarity Therapeutics Stock FAQ

What is Allarity Therapeutics's quote symbol?

(NASDAQ: ALLR) Allarity Therapeutics trades on the NASDAQ under the ticker symbol ALLR. Allarity Therapeutics stock quotes can also be displayed as NASDAQ: ALLR.

If you're new to stock investing, here's how to buy Allarity Therapeutics stock.

What is the 52 week high and low for Allarity Therapeutics (NASDAQ: ALLR)?

(NASDAQ: ALLR) Allarity Therapeutics's 52-week high was $103.80, and its 52-week low was $0.61. It is currently -98.9% from its 52-week high and 85.67% from its 52-week low.

How much is Allarity Therapeutics stock worth today?

(NASDAQ: ALLR) Allarity Therapeutics currently has 17,014,737 outstanding shares. With Allarity Therapeutics stock trading at $1.14 per share, the total value of Allarity Therapeutics stock (market capitalization) is $19.40M.

Allarity Therapeutics stock was originally listed at a price of $10,605,106.05 in Dec 22, 2021. If you had invested in Allarity Therapeutics stock at $10,605,106.05, your return over the last 3 years would have been -100%, for an annualized return of -99.52% (not including any dividends or dividend reinvestments).

How much is Allarity Therapeutics's stock price per share?

(NASDAQ: ALLR) Allarity Therapeutics stock price per share is $1.14 today (as of Apr 29, 2025).

What is Allarity Therapeutics's Market Cap?

(NASDAQ: ALLR) Allarity Therapeutics's market cap is $19.40M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Allarity Therapeutics's market cap is calculated by multiplying ALLR's current stock price of $1.14 by ALLR's total outstanding shares of 17,014,737.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.